Skip navigation
Home
Menu
Menu
Study
Student life
Research and innovation
Global
About us
Staff
Students
Search the site
Centre of Excellence for Long-acting Therapeutics
Menu
About us
LONGEVITY Project
Nanotherapeutics Hub
Teoreler
PKRxiv
LAPaL
Blog
Our News
Events
Contact us
News
Novo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD
17 January 2025
Long-acting Injectables: Microsphere Design, Development and Scale-up Using Lactide/Glycolide-Based Polymers, Upcoming Webinar Hosted by Xtalks
17 January 2025
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
17 January 2025
Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral
17 January 2025
WHO announces the development of new guidelines for lenacapavir and updated HIV testing guidelines
10 January 2025
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
27 December 2024
ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe
20 December 2024
Johnson & Johnson denied extension of patent on TB drug, to benefit patients
20 December 2024
Neuraxpharm and Pharmathen enter into strategic co-development agreement to develop long-acting injectable therapies
13 December 2024
Global leaders in the HIV response call for access to long-acting medicines
13 December 2024
News
Novo Holdings invests in $200M Series A for Windward Bio launch to advance long-acting treatments for asthma and COPD
17 January 2025
Long-acting Injectables: Microsphere Design, Development and Scale-up Using Lactide/Glycolide-Based Polymers, Upcoming Webinar Hosted by Xtalks
17 January 2025
Glaukos Announces Positive Clinical Updates for its iDose® Sustained-Release Procedural Pharmaceutical Platform
17 January 2025
Lyndra Therapeutics Announces Strategic Clinical Research and Commercial Manufacturing Services Collaboration with Thermo Fisher Scientific for Long-Acting Oral
17 January 2025
WHO announces the development of new guidelines for lenacapavir and updated HIV testing guidelines
10 January 2025
Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-001, its Novel Half-life Extended Anti-IL-23p19 Antibody
27 December 2024
ViiV Healthcare announces CHMP positive opinion for Vocabria + Rekambys, the first and only complete long-acting HIV treatment, for adolescents in Europe
20 December 2024
Older Stories
.jpg)
